Complement activation by beta-amyloid in Alzheimer disease.

AUTOR(ES)

Rogers, J

RESUMO

Alzheimer disease (AD) is characterized by excessive deposition of the beta-amyloid peptide (beta-AP) in the central nervous system. Although several lines of evidence suggest that beta-AP is neurotoxic, a mechanism for beta-AP toxicity in AD brain remains unclear. In this paper we provide both direct in vitro evidence that beta-AP can bind and activate the classical complement cytolytic pathway in the absence of antibody and indirect in situ evidence that such actions occur in the AD brain in association with areas of AD pathology.

Documentos Relacionados

• Beta-amyloid gene dosage in Alzheimer's disease.
• In situ hybridization of nucleus basalis neurons shows increased beta-amyloid mRNA in Alzheimer disease.
• Topographical relationship between beta-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease.
• Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide.
• Inhibition of Alzheimer's disease beta-amyloid aggregation, neurotoxicity and in vivo deposition